NCT03519230 2026-03-16
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT04164199 2026-03-16
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Enrolling by invitation
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT05526924 2026-03-04
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT05038839 2025-11-20
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting